People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

45.91USD
24 Oct 2014
Price Change (% chg)

$0.63 (+1.39%)
Prev Close
$45.28
Open
$45.57
Day's High
$46.39
Day's Low
$45.27
Volume
760,917
Avg. Vol
875,049
52-wk High
$54.25
52-wk Low
$34.28

Search Stocks

Ehrich, Elliot 

Brief Biography

Dr. Elliot W. Ehrich is Senior Vice President - Research and Development, Chief Medical Officer of Alkermes Plc. Until September 16, 2011, Dr. Ehrich served Senior Vice President of Research and Development and Chief Medical Officer at Alkermes. From May 2007 to September 2011, Dr. Ehrich also led the Research and Development, Clinical Sciences and Drug Safety functions at Alkermes. Prior to assuming this position in May 2007, Dr. Ehrich served as Vice President, Science Development and Chief Medical Officer of Alkermes. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., Inc. ("Merck"), a publicly traded pharmaceutical company, overseeing the clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. Dr. Ehrich worked as a research associate at the European Molecular Biology Laboratory in Heidelberg, Germany before attending medical school. Dr. Ehrich is a member of the scientific advisory board for Aileron Therapeutics, a privately held biopharmaceutical company.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
435,458 -- 1,383,980 2,117,340

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 312,247 2,622,080.00
Name Fiscal Year Total

Richard Pops

6,587,780

Shane Cooke

3,164,580

James Frates

1,831,190

Gordon Pugh

1,965,720

Kathryn Biberstein

2,113,310

Rebecca Peterson

--
As Of 30 Mar 2013
Search Stocks